Key points are not available for this paper at this time.
Design
Review
Conflicting adiponectin data warrant caution against its use as a cardiometabolic biomarker; leaves open the need for standardized prospective studies.
Based on available data, adiponectin represents a multifaceted biomarker that may beneficially affect atherosclerosis, inflammation and insulin resistance pathways. However, there are conflicting results with regard to the associations between adiponectin levels and the prevalence and outcomes of cardiometabolic diseases. Further research on the potential clinical implications of adiponectin in the diagnosis and treatment of such diseases is needed.
No takes yet. Share an insight, caveat, or question.
Katsiki et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: